SERUM TESTOSTERONE CONCENTRATIONS AND RELATED FACTORS TO MALE HYPOGONADISM AT CAN THO UNIVERSITY OF MEDICINE AND PHARMACY HOSPITAL

Trung Hieu Nguyen1,, Thanh Binh Le 1, Huynh Tuan Tran 1, Quang Trung Le 1, Vo Tan Phat Quach1, Van Nghia Nguyen1, Van Huynh Duong 1, Dai Nghia Nguyen1, Quoc Cuong Tran 1, Viet Tu Le 1
1 Can Tho University of Medicine and Pharmacy

Main Article Content

Abstract

Background: Hypogonadism is defined by the European Association of Urology as a disorder associated with decreased testicular function, with decreased production of androgens and/or impaired sperm production. Testosterone deficiency can cause insulin resistance, obesity, hyperlipidemia, hypertension, and symptoms of male hypogonadism. Many patients are coming to the doctor because of symptoms of hypogonadism, but there is still no research evaluating serum testosterone levels and some related factors in these patients. Objectives: To survey serum testosterone levels and related factors to male hypogonadism at Can Tho University of Medicine and Pharmacy Hospital. Materials and methods: This was cross-sectional study, 73 male patients with symptoms of hypogonadism from 11/2022 to 6/2023 in Can Tho University of Medicine and Pharmacy Hospital. Results: The average age of patients was 65,6 ± 10,5. Symptoms of male hypogonadism: decreased libido 68.1%; decreased erection 72.2%; reduced labor productivity 76.4%. The average total testosterone concentration is 6.6 nmol/L, serum concentration testosterone <8 nmol/L accounts for 77.8%, and serum testosterone concentration 8-12 nmol/L accounts for 22.2%. There is a relationship between testosterone levels: aging, the degree of erectile dysfunction, history of SARS-Cov-2 infection. Conclusion: Patients with symptoms of hypogonadism should be evaluated for factors such as blood testosterone levels, metabolic syndrome, level of erectile dysfunction, and history of COVID-19 infection to help make treatment more complete and effective.

Article Details

References

1. Salonia A, et al. Male hypogonadism. EAU Guidelines on sexual and reproductive health. 2022. 13-38.
2. Salonia A., et al. Testosterone in males with COVID-19: A 7-month cohort study. Andrology. 2022. 10(1), 34-4, https://doi.org/10.1111/andr.13097.
3. Nguyễn Hòa Khánh. Nghiên cứu tỉ lệ bệnh danh yhct trên bệnh nhân nam suy sinh dục khởi phát muộn (LOH) tại bệnh viện ĐKKV Long Thành, tỉnh Đồng Nai. 2016. Luận văn thạc sĩ. Đại học Y dược TP Hồ Chí Minh.
4. Wei Chen, Zhi-Yong Liu, Lin-Hui Wang, et al. Are the Aging Male's Symptoms (AMS) scale and the Androgen Deficiency in the Aging Male (ADAM) questionnaire suitable for the screening of late-onset hypogonadism in aging Chinese men?. Aging Male. 2013. 16(3), 92-6, https://doi.org/10.3109/13685538.2013.805319.
5. A Morelli, G Corona, S Filippi, et al. Which patients with sexual dysfunction are suitable for testosterone replacement therapy?. J Endocrinol Invest. 2007. 30(10), 880-8, https://doi.org/10.1007/bf03349232.
6. Peeyush Kumar, Nitish Kumar, Devendra Singh Thakur, et al. Male hypogonadism: Symptoms and treatment. J Adv Pharm Technol Res. 2020. 1(3), 297-301, https://doi.org/10.4103%2F0110-5558.72420.
7. Meili Cai, Ran Cui, Peng Yang, et al. Incidence and Risk Factors of Hypogonadism in Male Patients With Latent Autoimmune Diabetes and Classic Type 2 Diabete. Front Endocrinol (Lausanne). 2021. 12, 675525, https://doi.org/10.3389/fendo.2021.675525.
8. Rastrelli G., Di Stasi V., Inglese F., et al. Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. Andrology. 2021.9, 88–98, https://doi.org/10.1111/andr.12821.
9. Yamamoto Y, Otsuka Y, et al. Detection of Male Hypogonadism in Patients with Post COVID19 Condition. J Clin Med. 2022. 31.11(7),1955, https://doi.org/10.3390/jcm11071955.